GlassScriptPhysician profile
Douglas N Zlock
NPI 1427082692
$736.55
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $159 · 2021: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.35 | 2019-2020 | |
| Novo Nordisk INC | $136.19 | 2020-2021 | |
| Abbott Laboratories | $119.33 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $87.32 | 2019 | |
| Mannkind Corporation | $80.01 | 2019 | |
| Medtronic, INC. | $46.80 | 2021 | |
| Lilly USA, LLC | $23.93 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.61 | 2020 | |
| Companion Medical, INC. | $16.91 | 2019 | |
| Insulet Corporation | $14.10 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Zlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.